论文部分内容阅读
成功使用静注完整免疫球蛋白(IGIV)于1979年首次报道。IGIV副作用小,正常半衰期长达25～28d,并且疗效确凿。随后,第二代和第三代IGIV相继推出,其商品在世界各地均有售。现在IGIV治疗原发性免疫缺陷病已很成熟,更为重要的是其适应症已扩展到各种继发性免疫缺陷病、自身免疫性疾病和感染性疾病。 IGIV的药动学市场上液体或脂质化的IGIV制剂由健
The successful use of intravenous intact immunoglobulin (IGIV) was first reported in 1979. IGIV side effects, the normal half-life of up to 25 ~ 28d, and the efficacy of conclusive. Subsequently, the second and third generation IGIV have been launched, their products are sold all over the world. IGIV is now well established for treating idiopathic immunodeficiency disease, and more importantly, its indications have been extended to various forms of secondary immunodeficiency, autoimmune and infectious diseases. IGIV pharmacokinetics on the market liquid or lipidated IGIV formulations by Kin